Alteration of neuromuscular function after a prolonged road cycling race.

Int J Sports Med

INSERM/ERITm, Faculté des Sciences du Sport, Université de Bourgogne, BP 27 877, 21078 Dijon Cedex, France.

Published: April 2003

The aim of this study was to characterize neuromuscular fatigue in knee extensor muscles after a prolonged cycling exercise. During the two days preceding a 140-km race (mean +/- SD duration: 278.2 +/- 24.9 min) and 15 to 30 min after, maximal percutaneous electrical stimulations were applied to the femoral nerve of 11 trained cyclists. Electrically evoked superimposed twitches and trains of 6 stimulations were delivered during isometric maximal voluntary contraction (MVC) to determine maximal voluntary activation (% VA). Knee extensors MVC decreased with fatigue from 158.2 +/- 29.6 to 144.2 +/- 30.0 Nm (p < 0.01), but no central activation failure was detected after the race. The average rate of twitch force development increased significantly from 414 +/- 106 to 466 +/- 102 N x m x s-1 (p < 0.05) and a tendency toward higher peak twitch tension (p = 0.052) was found in the fatigued state. Short tetanus at 20 Hz and 80 Hz were also applied to 4 cyclists, but these fused and unfused tetanic forces were not significantly modified with fatigue. From these results, it can be concluded that the small but significant isometric strength loss measured less than 30 min after the end of a long distance road cycling race is not due to central fatigue. It is also suggested that a raise in peak twitch tension is not necessarily associated with enhanced neuromuscular function.

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-2003-39088DOI Listing

Publication Analysis

Top Keywords

neuromuscular function
8
road cycling
8
cycling race
8
maximal voluntary
8
peak twitch
8
twitch tension
8
+/-
6
alteration neuromuscular
4
function prolonged
4
prolonged road
4

Similar Publications

Resistance training (RT) load and volume are considered crucial variables to appropriately prescribe and manage for eliciting the targeted acute responses (i.e., minimizing neuromuscular fatigue) and chronic adaptations (i.

View Article and Find Full Text PDF

Review of upper extremity passive joint impedance identification in people with Duchenne Muscular Dystrophy.

J Neuroeng Rehabil

January 2025

Department of BioMechanical Engineering, Delft University of Technology, Mekelweg 2, Delft, 2628 CD, South-Holland, The Netherlands.

Duchenne Muscular Dystrophy (DMD) progressively leads to loss of limb function due to muscle weakness. The incurable nature of the disease shifts the focus to improving quality of life, including assistive supports to improve arm function. Over time, the passive joint impedance (Jimp) of people with DMD increases.

View Article and Find Full Text PDF

The neuromuscular junction (NMJ) is essential for transmitting signals from motor neurons (MNs) to skeletal muscles (SKMs), and its dysfunction can lead to severe motor disorders. However, our understanding of the NMJ is limited by the absence of accurate human models. Although human induced pluripotent stem cell (iPSC)-derived models have advanced NMJ research, their application is constrained by challenges such as limited differentiation efficiency, lengthy generation times, and cryopreservation difficulties.

View Article and Find Full Text PDF

Introduction: Patients with peripheral artery disease (PAD) can experience intermittent claudication, which limits walking capacity and the ability to undertake daily activities. While exercise therapy is an established way to improve walking capacity in people with PAD, it is not feasible in all patients. Neuromuscular electrical stimulation (NMES) provides a way to passively induce repeated muscle contractions and has been widely used as a therapy for chronic conditions that limit functional capacity.

View Article and Find Full Text PDF

Background: Evidence from preclinical studies suggests that IL-6 signalling has the potential to modulate immunopathogenic mechanisms upstream of autoantibody effector mechanisms in patients with generalised myasthenia gravis. We aimed to assess the safety and efficacy of satralizumab, a humanised monoclonal antibody targeting the IL-6 receptor, in patients with generalised myasthenia gravis.

Methods: LUMINESCE was a randomised, double-blind, placebo-controlled, multicentre, phase 3 study at 105 sites, including hospitals and clinics, globally.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!